Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Keith_Blundy
|
| gptkbp:developedBy |
small molecule inhibitors
|
| gptkbp:focusesOn |
drug discovery
RNA epigenetics RNA-modifying enzymes |
| gptkbp:foundedYear |
2015
|
| gptkbp:founder |
gptkb:Eric_Miska
gptkb:Tony_Kouzarides |
| gptkbp:headquartersLocation |
gptkb:Cambridge,_United_Kingdom
|
| https://www.w3.org/2000/01/rdf-schema#label |
STORM Therapeutics
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:investor |
gptkb:IP_Group
gptkb:Pfizer_Ventures gptkb:Cambridge_Innovation_Capital gptkb:Merck_Ventures |
| gptkbp:notableContributor |
METTL3 inhibitors
targeting RNA methyltransferases |
| gptkbp:therapeuticArea |
gptkb:cancer
oncology |
| gptkbp:website |
https://www.stormtherapeutics.com/
|
| gptkbp:bfsParent |
gptkb:Tony_Kouzarides
|
| gptkbp:bfsLayer |
6
|